2024
Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial)
Zeng L, Perin J, Gross A, Shade D, Lanctôt K, Lerner A, Mintzer J, Brawman‐Mintzer O, Padala P, van Dyck C, Porsteinsson A, Craft S, Levey A, Herrmann N, Rosenberg P. Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial). International Journal Of Geriatric Psychiatry 2024, 39: e6108. PMID: 38858522, PMCID: PMC11265565, DOI: 10.1002/gps.6108.Peer-Reviewed Original ResearchConceptsMethylphenidate groupTreating apathyPlacebo-controlled trial of methylphenidateTreatment of apathyAssociated with methylphenidateEffects of methylphenidateTrial of methylphenidateAlzheimer's diseaseFollow-upNo treatment group differencesAdverse effects of methylphenidateDiastolic blood pressureSymptom ChecklistAdverse eventsTreatment group differencesMonitoring weightMethylphenidate useMethylphenidate treatmentMedical comorbiditiesPlacebo groupParticipantsMethylphenidateGroup differencesPlacebo-controlled trialMonthly visits
2023
P104: Heterogeneity of Response to methylphenidate in apathetic patients in the ADMET 2 Trial
Lanctôt K, Rivet L, Tumati S, Perin J, Vieira D, Rosenberg P, Herrmann N, Lerner A, Padala P, Brawman-Mintzer O, van Dyck C, Porsteinsson A, Craft S, Levey A, Mintzer J. P104: Heterogeneity of Response to methylphenidate in apathetic patients in the ADMET 2 Trial. International Psychogeriatrics 2023, 35: 125-126. DOI: 10.1017/s1041610223002557.Peer-Reviewed Original ResearchPotential predictors of treatment outcomePredictors of treatment outcomeResponse to methylphenidateClinically significant apathyAlzheimer's Disease Cooperative Study ActivitiesMedium effect sizeMonths of methylphenidateAlzheimer's diseaseNPI-aMethylphenidate treatmentSignificant apathyApathetic patientsBaseline anxietyAD participantsMethylphenidatePotential predictorsActivities of Daily Living ScaleCompared to placeboNeuropsychiatric symptomsIndex scoreDaily Living ScaleAlzheimer's Disease Cooperative Study Activities of Daily Living ScaleApathyEffect sizeLiving scaleCost consequence analysis of Apathy in Dementia Methylphenidate Trial 2 (ADMET 2).
Lanctôt K, Chen C, Mah E, Kiss A, Li A, Shade D, Scherer R, Vieira D, Coulibaly H, Rosenberg P, Lerner A, Padala P, Brawman-Mintzer O, van Dyck C, Porsteinsson A, Craft S, Levey A, Burke W, Mintzer J, Herrmann N. Cost consequence analysis of Apathy in Dementia Methylphenidate Trial 2 (ADMET 2). International Psychogeriatrics 2023, 35: 664-672. PMID: 37066690, PMCID: PMC10579450, DOI: 10.1017/s1041610223000327.Peer-Reviewed Original ResearchConceptsCost-consequence analysisTreatment of apathyFive-level questionnaireTrial 2Quality of lifeBinary logistic regressionPlacebo groupPlacebo treatmentMethylphenidate treatmentSignificant apathyHealth utilityResource utilization costsAlzheimer's diseaseLogistic regressionMethylphenidateTime interactionLevel questionnaireHealthcare systemCost predictorsMeasures analysisPatientsTreatmentDiseaseMonthsUtilization costsCost Consequence Analysis of ADMET 2
Mah E, Lanctôt K, Chen Q, Shade D, Scherer R, Vieira D, Coulibaly H, Rosenberg P, Lerner A, Padala P, Brawman-Mintzer O, van Dyck C, Porsteinsson A, Mintzer J, Herrmann N. Cost Consequence Analysis of ADMET 2. American Journal Of Geriatric Psychiatry 2023, 31: s101. DOI: 10.1016/j.jagp.2022.12.147.Peer-Reviewed Original ResearchCost-consequence analysisHealth utilityPlacebo groupMethylphenidate treatmentEuroQol-five dimensions-five levelsAlzheimer's diseaseHealth statesCommon neuropsychiatric symptomsHealth utility scoresQuality of lifeBinary logistic regressionApathy treatmentBaseline demographicsDifferent time pointsPreference-based measuresMethylphenidate groupNeuropsychiatric symptomsClinical trialsEQ-5DSignificant apathyPatientsUtility scoresBetter health stateLogistic regressionMethylphenidate